Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, 2019-nCoV) emerged in December 2019 and spread into a worldwide pandemic. More than 260 million people worldwide have been verifiably infected with Sars-CoV-2 (as of December 2021), with more than 5.2 million deaths. The number of human coronavirus disease 2019 (COVID-19) cases continues to rise as countries roll out their vaccine programs. There is a broad range of clinical presentations of COVID-19, including neurological manifestations [1]. It is estimated that 10%-30% of COVID-19 patients develop neurological symptoms in the acute phase, which may be the presenting sign. Neurological manifestations of COVID-19 include cerebrovascular disorders, including ischemic stroke and macro/microhemorrhages, encephalopathies and (meningo-)encephalitis, para-/postinfectious immune-mediated complications such as Guillain-Barré syndrome, movement disorders, and neuropsychiatric complications [2-4]. In parallel to the